|14.50|| +0.50 / +3.57%|
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company which engages in research, discovery, development and commercialization of proprietary drugs based on prostones and other novel drug technologies. Prostones are naturally occurring fatty acid metabolites with unique physiological activities and can be targeted for the treatment of unmet or underserved medical needs. It is focused on developing and commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and is also considering other potential therapeutic applications of its drug technologies. The company was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.
|Peter S. Greenleaf||Chief Executive Officer & Director|
|Andrew P. Smith||Chief Financial Officer|
|Taryn R. Joswick||Vice President-Clinical Development|
|Peter Alec Kiener||Chief Scientific Officer|
|Thomas J. Knapp||Secretary, Chief Legal Officer & Executive VP|